earnings reports

J&J expects COVID-19 vaccine sales to jump as much as 46% in 2022

J&J expects COVID-19 vaccine sales to jump as much as 46% in 2022

J&J. Vials labeled 'COVID-19 Coronavirus Vaccine' and a syringe are seen in front of the Johnson & Johnson logo in this illustration taken February 9, 2021.

Dado Ruvic/Reuters

J&J sees $3.5 billion coming from its COVID-19 vaccine in 2022, a small part of its overall sales as the company sells the vaccine at a not-for-profit price

Johnson & Johnson on Tuesday, January 25, forecast as much as $3.5 billion in sales of its COVID-19 vaccine in 2022, a 46% jump for the shot that has fared poorly compared to rivals.

The drugmaker reported sales of $2.39 billion for the COVID-19 shot in 2021, missing its own target of $2.5 billion in a year marked by manufacturing stumbles, safety concerns, and uneven demand for the vaccine once touted as a promising tool for inoculating populations in hard-to-reach areas.

Pfizer by comparison is forecasting $29 billion in 2022 sales of the COVID-19 vaccine it developed with German partner BioNTech SE, while Moderna is projecting $18.5 billion in vaccine sales this year.

J&J, the world’s largest healthcare conglomerate, is planning to separate its consumer health unit to focus on its large pharmaceuticals and COVID-battered medical devices units.

J&J forecast total 2022 sales that topped Wall Street estimates. That was mostly driven by its vaccine sales forecast exceeding analysts’ low expectations for the shot J&J sells at a not-for-profit price.

Overall, fourth-quarter sales of $24.80 billion missed analysts’ expectations of $25.29 billion, according to Refinitiv data, as big revenue drivers such as cancer drug Imbruvica and Crohn’s disease treatment Stelara came up short.

Imbruvica, which J&J shares with AbbVie, had sales of $1.06 billion, below estimates of $1.17 billion. Stelara sales of $2.33 billion missed estimates of $2.45 billion.

J&J expects to appoint executives for its consumer health unit and announce a new name and headquarters for the business that sells mouthwash, bandages, and non-prescription medicines sometime in the first half of 2022, chief financial officer Joseph Wolk said on conference call.

Sales of $6.86 billion for the medical devices segment also missed estimates of $6.98 billion.

J&J chief executive Joaquin Duato said he was confident in the recovery of that business as delayed non-urgent procedures come back on track as the latest pandemic surge eases.

Overall, J&J expects 2022 sales of $98.9 billion to $100.4 billion, above Wall Street estimates of $97.79 billion. – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.